Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics

E. Campo, F. Cymbalista, P. Ghia, U. Jäger, S. Pospisilova, R. Rosenquist, A. Schuh, S. Stilgenbauer,

. 2018 ; 103 (12) : 1956-1968. [pub] 20181115

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045135

Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is partly due to genetic aberrations identified in chronic lymphocytic leukemia cells such as mutations of TP53 and/or deletions in chromosome 17p [del(17p)], resulting in loss of one TP53 allele. These aberrations are associated with markedly decreased survival and predict impaired response to chemoimmunotherapy thus being among the strongest predictive markers guiding treatment decisions in chronic lymphocytic leukemia. Clinical trials demonstrate the importance of accurately testing for TP53 aberrations [both del(17p) and TP53 mutations] before each line of treatment to allow for appropriate treatment decisions that can optimize patients' outcomes. The current report reviews the diagnostic methods to detect TP53 disruption better, the role of TP53 aberrations in treatment decisions and current therapies available for patients with chronic lymphocytic leukemia carrying these abnormalities. The standardization in sequencing technologies for accurate identification of TP53 mutations and the importance of continued evaluation of TP53 aberrations throughout initial and subsequent lines of therapy remain unmet clinical needs as new therapeutic alternatives become available.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045135
003      
CZ-PrNML
005      
20200113081750.0
007      
ta
008      
200109s2018 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2018.187583 $2 doi
035    __
$a (PubMed)30442727
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Campo, Elias $u Hospital Clinic of Barcelona, University of Barcelona, Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Barcelona, and CIBERONC, Spain.
245    10
$a TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics / $c E. Campo, F. Cymbalista, P. Ghia, U. Jäger, S. Pospisilova, R. Rosenquist, A. Schuh, S. Stilgenbauer,
520    9_
$a Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is partly due to genetic aberrations identified in chronic lymphocytic leukemia cells such as mutations of TP53 and/or deletions in chromosome 17p [del(17p)], resulting in loss of one TP53 allele. These aberrations are associated with markedly decreased survival and predict impaired response to chemoimmunotherapy thus being among the strongest predictive markers guiding treatment decisions in chronic lymphocytic leukemia. Clinical trials demonstrate the importance of accurately testing for TP53 aberrations [both del(17p) and TP53 mutations] before each line of treatment to allow for appropriate treatment decisions that can optimize patients' outcomes. The current report reviews the diagnostic methods to detect TP53 disruption better, the role of TP53 aberrations in treatment decisions and current therapies available for patients with chronic lymphocytic leukemia carrying these abnormalities. The standardization in sequencing technologies for accurate identification of TP53 mutations and the importance of continued evaluation of TP53 aberrations throughout initial and subsequent lines of therapy remain unmet clinical needs as new therapeutic alternatives become available.
650    12
$a chromozomální delece $7 D002872
650    _2
$a lidské chromozomy, pár 17 $x genetika $7 D002886
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x diagnóza $x genetika $x terapie $7 D015451
650    12
$a mutace $7 D009154
650    _2
$a prognóza $7 D011379
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Cymbalista, Florence $u Hôpital Avicenne, AP-HP, UMR INSERMU978/Paris 13 University, Bobigny, France.
700    1_
$a Ghia, Paolo $u Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy ghia.paolo@hsr.it.
700    1_
$a Jäger, Ulrich $u Medical University of Vienna, Austria.
700    1_
$a Pospisilova, Sarka $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Rosenquist, Richard $u Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Schuh, Anna $u University of Oxford, UK.
700    1_
$a Stilgenbauer, Stephan $u Internal Medicine III, Ulm University, Germany and Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg, Germany.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 103, č. 12 (2018), s. 1956-1968
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30442727 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113082122 $b ABA008
999    __
$a ok $b bmc $g 1483404 $s 1083808
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 103 $c 12 $d 1956-1968 $e 20181115 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace